12/14/10 | Solving Problems for the Clean Energy Industry: Collaboration between Lawrence Berkeley National Laboratory and NIREC to Accelerate the Commercialization of Clean Energy Technologies |
This pilot program pairs NIREC's Entrepreneur-In-Residence (EIR) Program with Berkeley Lab's world-class clean energy research to meet defined market needs. | |
12/14/10 | Rive Technology Raises $25 Million in Series C Financing |
Financing, Led by The Blackstone Group, to Support Commercial Trials & Global Deployment of Catalyst Technology | |
12/14/10 | Cancer Targeted Technology (CTT) Enters into a Research and License Option Agreement with Bayer Pharma AG to Advance a Cancer PET Imaging Agent toward Clinical Trials |
Under the terms of the agreement, CTT will receive R&D funding and, if the option is exercised, could receive payments on the achievement of development milestones, as well as royalties on sales of products resulting from the collaboration. | |
12/14/10 | Pulmatrix Receives $5.7 Million from DARPA |
Part of the 7-Day Biodefense Initiative for Development of Inhaled Therapeutics for Warfighters | |
12/14/10 | Soladigm Secures $30 Million Series C Equity Financing From GE, DBL Investors, Nano Dimension and Existing Investors |
Soladigm is a developer of next-generation green building solutions designed to improve energy efficiency. | |
12/13/10 | Yissum Introduces a Novel Method for Forensic DNA Profiling |
- Method enables accurate identification of a suspect's DNA in crime scenes even when DNA evidence comprises a mixture from multiple individuals - | |
12/10/10 | U.S. Army Awards Researcher at Children’s Hospital Los Angeles $1.05 Million to Develop Next Generation Gene Sequencing Facility |
Whole genome characterization core facility will employ clinically applicable, state-of-the-art sequencing technology | |
12/06/10 | 3M to Acquire Winterthur Technologies AG |
Acquisition Enhances Abrasives Offering | |
12/02/10 | Merck to Acquire SmartCells, Inc. |
SmartCells' core technology was originally developed at The Massachusetts Institute of Technology by its president, co-founder and chief executive officer Dr. Todd Zion. | |
11/30/10 | UCSF Works with Anacor Pharmaceuticals and New York Blood Center to Discover Drugs for River Blindness |
The collaboration will combine Anacor’s novel boron-based chemistry platform and drug discovery and development capabilities with the Sandler Center’s expertise in neglected disease biology and drug discovery and the LFKRI’s expertise in onchocerciasis. | |
[ <- 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 -> ] |